Sign in

Endometrial cancer

Current status: Curable in many cases

A cancer that starts in the lining of the womb, and usually happens after the menopause. The main sign is bleeding from the vagina after the menopause, between periods, or heavier than is normal for you. The most common treatment is surgery to remove the womb, sometimes with radiotherapy, chemotherapy or hormone medicine. Most cases are found early, before the cancer has spread, and these are usually cured.

Read more about endometrial cancer
Where research stands todayUpdated 17 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsFrance, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 2Taking people
    Tests relacorilant with other treatments for gynecological cancers

    Tests relacorilant with other drugs in adults with ovarian or endometrial cancer.

    Lille, FranceAlso Nancy, Nice, Pierre-Bénite, Plérin, ToulouseAge 18+
  2. Trial-stage treatmentPhase 3Taking people
    Tests trastuzumab deruxtecan with immunotherapy for HER2-expressing endometrial cancer

    Tests a HER2-targeted drug with immunotherapy as first treatment in adults with advanced endometrial cancer.

    Bordeaux, FranceAlso Lyon, Paris, Plérin, PoitiersAge 18+
  3. Trial-stage treatmentPhase 1/2Taking people
    Tests GSK5460025 alone or combined with other drugs in solid tumors

    Tests the pill GSK5460025 in adults with certain solid tumors that have specific genetic traits.

    Lyon, FranceAlso Saint-Herblain, VillejuifAge 18+
  4. Trial-stage treatmentPhase 2Taking people
    Tests lighter follow-up treatment for early endometrial cancer with certain tumor gene profiles

    Tests reduced treatment after surgery in adults with early endometrial cancer.

    Lille, FranceAlso Lyon, Paris, Toulouse, VillejuifAge 18+
  5. Trial-stage treatmentPhase 3Taking people
    Tests BNT323 or chemotherapy in people with recurring HER2-expressing uterine cancer

    Compares BNT323 with chemotherapy in adults with recurring uterine cancer previously treated with immunotherapy.

    Angers, FranceAlso Le Mans, Marseille, ParisAge 18+
  6. Trial-stage treatmentPhase 1Soon in France
    Tests CTIM-76 in adults with recurring ovarian cancer and other solid tumors

    Tests CTIM-76 in adults with advanced ovarian, testicular or endometrial cancer.

    Lyon, FranceAlso VillejuifAge 18+
  7. Trial-stage treatmentPhase 3Taking people
    Tests sacituzumab tirumotecan with pembrolizumab in endometrial cancer

    Tests sacituzumab tirumotecan plus pembrolizumab in adults with advanced endometrial cancer.

    Bordeaux, FranceAlso Lyon, Marseille, Paris, Plérin, Saint-CloudAge 18+
  8. Trial-stage treatmentPhase 1/2Taking people
    Tests VS-7375 in adults with advanced solid tumors carrying a KRAS G12D mutation

    Tests the drug VS-7375, alone or combined, in adults with advanced KRAS G12D-mutated cancers.

    Lyon, FranceAlso Marseille, ParisAge 18+
  9. Trial-stage treatmentPhase 1Taking people
    Tests Sofe-M in adults with selected advanced solid tumors

    Tests whether Sofe-M is safe and tolerable in adults with advanced solid tumors.

    Lyon, FranceAge 18+
  10. Trial-stage treatmentPhase 2Taking people
    Tests sevabertinib in solid tumors with HER2 gene mutations

    Tests sevabertinib tablets in adults with solid tumors carrying HER2 mutations.

    Bordeaux, FranceAlso Brest, Lille, Montpellier, Pierre-Bénite, VillejuifAge 18+
  11. Trial-stage treatmentPhase 3Taking people
    Compares Rina-S with standard chemotherapy in endometrial cancer

    Tests Rina-S against standard chemotherapy in adults with recurrent endometrial cancer.

    Angers, FranceAlso Bayonne, Bordeaux, Brest, Clermont-Ferrand, Dijon, Grenoble, Montpellier, Nancy, …Age 18+
  12. Trial-stage treatmentPhase 1/2Taking people
    EIK1005 alone or with pembrolizumab for advanced solid tumors

    Tests EIK1005, alone and with pembrolizumab, in adults with advanced solid tumors.

    Pierre-Bénite, FranceAge 18+
  13. Trial-stage treatmentPhase 3Taking people
    Tests trastuzumab deruxtecan after surgery for HER2-expressing endometrial cancer

    Tests trastuzumab deruxtecan against standard chemotherapy in adults with HER2-expressing endometrial cancer.

    Bordeaux, FranceAlso Brest, Lille, Pierre-Bénite, VillejuifAge 18+
  14. Trial-stage treatmentPhase 2Taking people
    Tests patritumab deruxtecan in adults with several advanced solid tumors

    Tests patritumab deruxtecan in adults with advanced solid tumors, including melanoma and gastric cancer.

    Bordeaux, FranceAlso Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, VillejuifAge 18+
  15. Trial-stage treatmentPhase 1/2Taking people
    Tests ifinatamab deruxtecan in several types of recurrent or spreading solid tumors

    Tests ifinatamab deruxtecan in adults with solid tumors that returned or spread.

    Bordeaux, FranceAlso Lyon, Paris, VillejuifAge 18+
  16. Trial-stage treatmentPhase 1/2Taking people
    Tests ART0380 Pill Alone or With Chemotherapy for Advanced Solid Tumors

    Tests the ART0380 pill, alone or with chemotherapy, in adults with advanced solid tumors.

    Bordeau, FranceAlso Marseille, Paris, Poitiers, VillejuifAge 18+
  17. Trial-stage treatmentPhase 1Taking people
    Tests XmAb541 for safety in people with advanced solid tumors

    Tests the new drug XmAb541 for safety and dosing in advanced ovarian and endometrial cancers.

    Pierre-Bénite, FranceAge 15+
  18. Trial-stage treatmentPhase 3Taking people
    Testing radiotherapy with durvalumab after surgery for mismatch-repair deficient endometrial cancer

    Compares radiotherapy with durvalumab against radiotherapy with or without chemotherapy in endometrial cancer.

    Bordeaux, FranceAlso Lyon, Marseille, VillejuifAge 18+
  19. Trial-stage treatmentPhase 1/2Taking people
    Tests rezatapopt in advanced solid tumors with a TP53 Y220C mutation

    Tests rezatapopt, alone or with pembrolizumab, in people with advanced TP53 Y220C tumors.

    Bordeaux, FranceAlso Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, VillejuifAge 12+
  20. Trial-stage treatmentPhase 1/2Taking people
    Tests ubamatamab alone or with cemiplimab in recurrent ovarian and uterine cancers

    Tests ubamatamab, alone or with cemiplimab, in adults with recurrent ovarian or uterine cancer.

    Bordeaux, FranceAlso Lyon, Pierre-BéniteAge 18+

Trials that have ended are not listed here, because nobody can join them. Stopped and finished Endometrial cancer trials (research view)

Take part in research

14 official research programmes take people with this disease. In a biobank or a registry you give a blood or tissue sample, or your health data, for many research teams to use.

See the research programmes

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

Most people are found at an early stage, when this cancer is usually cured; once it has spread far, it is rarely cured.

Approved: 7

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 27

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 2

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 4

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Words used here

Placebo: a dummy treatment without the medicine, used for comparison.

Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.

Where this comes from

The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.

A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.

The trials: ClinicalTrials.gov and the EU trials register, as copied into our trial database, checked on 12 November 2026. Every treatment in trials links to its own trial records; the texts are written by AI from them and checked against them by a second AI. People have not reviewed them yet. Placebo, standard medicines used for comparison and procedures are left out.

Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 87 other open phase 2 trials are not listed.

Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for endometrial (womb) cancer. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.

Not medical advice. Talk to your doctor before you change any treatment.

The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.

Support organisations

Patient organisations and helplines in France, for you and your family.

Endometrial cancer organisations in France

  • La Ligue contre le cancer

    Free cancer support line and local centres with supportive care, psychological support, financial aid and help with your rights.

  • Cancer Support France

    Charity supporting English-speaking people in France touched by cancer, offering free support to patients, carers and families (UICC member).

  • IMAGYN

    Association for women with gynaecological pelvic cancers incl. ovarian: information, support, webinars, events, IMAGYN Ecoute listening line (10-12 and 14-17). ENGAGe member.

  • Patients en Reseau (Mon Reseau Cancer du Poumon / Colorectal / du Sein)

    Patient association running free, moderated online communities per cancer (lung, colorectal, breast incl. metastatic content), information dossiers, events, webinars, meetups. LuCE and DiCE member.

General support in France

  • 3114 – Numéro national de prévention du suicide

    France's free 24/7 national suicide prevention number, answered by trained health professionals, for people in distress and their relatives.

  • S.O.S Amitié France

    French volunteer listening service offering anonymous, free, caring emotional support by phone, chat and messaging, day and night.

  • Santé.fr

    France's official public health information service (Ministry of Health) with reliable health information and a directory of care services.

International organisations

Patient organisation umbrella bodies

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.No open programme yet
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

7 medicines are approved for endometrial cancer in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 11 Nov 2026 in the official lists of the US (FDA), the EU (EMA), Japan (PMDA, approvals since April 2004), Switzerland (Swissmedic), France (ANSM, medicines approved in France only) and Taiwan (TFDA). For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. 4 uncertain matches are left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

About endometrial cancer

Sources: NHS, NCI PDQ, MedlinePlus, NCI SEER

A cancer that starts in the lining of the womb, and usually happens after the menopause. The main sign is bleeding from the vagina after the menopause, between periods, or heavier than is normal for you. The most common treatment is surgery to remove the womb, sometimes with radiotherapy, chemotherapy or hormone medicine. Most cases are found early, before the cancer has spread, and these are usually cured.

What is it?

The womb (uterus) is where a baby grows during pregnancy. Endometrial cancer starts in the womb's lining, the endometrium. It is the most common kind of womb cancer. The cause is not known, but too much of the hormone oestrogen raises the risk.

It is most common in people who have been through the menopause, but anyone with a womb can get it. Being overweight, some kinds of hormone replacement therapy (HRT), diabetes, never having given birth, a late menopause and the breast cancer medicine tamoxifen raise the risk. It is more likely if close family have had womb, bowel or ovarian cancer, or with an inherited condition called Lynch syndrome. A healthy weight, regular exercise and a balanced diet can lower your chances.

The first signs

The most common sign is bleeding from the vagina that is not normal for you.

  • bleeding or spotting after the menopause;
  • heavy periods that are unusual for you, or bleeding between periods;
  • a change in the discharge from your vagina;
  • pain in the lower back or between the hips (pelvis), or pain during sex;
  • a lump or swelling in your tummy, or peeing or pooing more or less often than usual.

How doctors find out

Your family doctor asks about your symptoms and may examine your tummy and vagina; you can ask for a female doctor or nurse. If cancer is possible, they send you to a specialist. You may have a scan with a small device placed in the vagina, blood tests, a look inside the womb with a thin camera (hysteroscopy), and a biopsy, where cells are taken from the womb lining. The tests can feel uncomfortable but should not hurt.

Results usually take a few weeks. If it is cancer, more scans (CT, MRI or PET) and genetic tests show how far it has spread. A specialist nurse is your main contact during and after treatment.

Current treatment

Surgery to remove the womb is the main treatment, sometimes followed by radiotherapy or chemotherapy to lower the chance of the cancer coming back; hormone therapy, immunotherapy or targeted medicines are used when it has spread or come back.

Will it get worse?

How serious it is depends on how big the cancer is, whether it has spread, and your general health. Irregular bleeding usually makes people see a doctor early, so most cases are found before the cancer has spread; about two in three are still only in the womb when found. Cancer that has spread to other parts of the body is rarely cured.

Medicines: what helps, and what to watch for

Chemotherapy uses medicines to kill cancer cells. It can be given after surgery to lower the chance of the cancer coming back, together with radiotherapy, or to slow the cancer and ease symptoms if it has spread. Hormone therapy blocks the hormones some of these cancers need to grow; it can help when the cancer has spread or you are not well enough for surgery or radiotherapy. Immunotherapy, which helps your immune system find and kill cancer cells, and targeted medicines may be options for advanced cancer or cancer that comes back.

Good to know:

  • Common side effects of chemotherapy are tiredness, feeling sick, a sore mouth, hair loss for a while, and numbness or tingling in the hands or feet;
  • Radiotherapy can cause tiredness, diarrhoea (which should go within a few weeks of treatment ending), vaginal dryness or narrowing, and the menopause;
  • You do not need to wait for your next check-up to raise a side effect that worries you.

Radiotherapy, for some people

Radiotherapy uses high-energy rays to kill cancer cells. It can come from a machine outside the body or from a source placed inside, near the cancer. It may be given after surgery to lower the chance of the cancer coming back, and it can be the main treatment if you cannot have surgery. It can also ease symptoms.

Surgery, for some people

Surgery is the most common treatment, especially for early cancer. The surgeon removes the womb and the neck of the womb (cervix) in an operation called a hysterectomy. Sometimes the ovaries and fallopian tubes, nearby lymph nodes or the upper part of the vagina are removed too. If the cancer has spread or come back, surgery may also remove nearby parts, such as the ovaries and tubes, the bladder or the rectum. Recovery can take a long time. Your team will talk with you about what treatment means for having children.

Is there a cure?

Yes, often. When the cancer is found early and is only in the womb, treatment usually cures it. When it has spread far, it is rarely cured, and treatment aims to control it. Clinical trials are testing new treatments, and joining one may be an option for some people.

See the 437 trials you can join

Median survival

About 3 years with chemotherapy for stage III or IV

Measured in: Stage III or IV, with chemotherapy: the GOG-0209 trial (1,381 women)

The figures behind it

NCI PDQ (health professional): in the GOG-0209 trial (1,381 women), median overall survival was 37 months with carboplatin plus paclitaxel and 41 months with paclitaxel, doxorubicin and cisplatin; in advanced or recurrent cancer after earlier platinum treatment, it was 18.7 months with pembrolizumab plus lenvatinib vs 11.9 months with chemotherapy (KEYNOTE-775). Most cases are found early, and localized disease is usually cured.